NCT05440708 2026-04-27A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaTvardi Therapeutics, IncorporatedPhase 1/2 Recruiting193 enrolled